To those of you who have family members with Fragile X, thank you for being interested in clinical trials! This is a challenging phase for all of us, and as exciting as it is, we know many of you have questions about what it means to be in a clinical trial.

Each study is supervised by a doctor that specializes in Fragile X. These trials are free, you do not have to tell your insurance company, and you can leave any time you want. Travel costs are usually covered.

The FDA requires two successful large-scale clinical trials before it will consider approving a new treatment. If studies are successful and the FDA approves new drugs, others with Fragile X can also have access to these medicines.

Clinical Trials and Studies recruiting patients

 Informational webinar by Dr. Alex Kolevzon, 10/15/2014

  PowerPoint Slides (download)

  • More about this trial

    The purpose of this study is to assess the safety and efficacy of two dose levels of NNZ-2566 when compared to placebo in adolescent and adult males (ages 14-40) who have been diagnosed with FXS.

    Neuren Brochure on Fragile X Syndrome

    Brochure to download and print

    NNZ-2566 has a novel mechanism of action compared with other drugs that have been tested for Fragile X syndrome. It is a modified version of a biologically active part of Insulin-like Growth Factor (IGF-1). IGF-1 is a protein that helps cells grow and respond to stress or damage. In the brain, IGF-1 contributes to the growth of brain cells and the connections between them (synapses).

    The biologically active part of IGF-1 is called glypromate or GPE and supports the function of brain cells in a different way than IGF-1.  GPE occurs naturally in the brain. NNZ-2566 is a version of GPE modified to make it available to take as an oral medication. NNZ-2566 may help improve brain function by enhancing functions normally performed by GPE and by increasing IGF-1 levels in the brain. NNZ-2566 has been shown in animal models of Fragile X to improve performance in tests of behavior and cognition.

    FDA has granted two special designations for Neuren’s development of NNZ-2566 in Fragile X: Fast Track Designation and Orphan Drug Designation.

    This trial will include 60 participants between the ages of 14-40. Taking part in this study involves 8 visits to the doctor’s office over 10 weeks. The study medication and all study-related evaluations will be provided at no cost. Some support for travel is available. 

  • Trial Sites

    Davis, California
    UC Davis MIND Institute
    Principal Investigator: Randi Hagerman, MD
    Contact: Lindsey Partington 916-703-0427 lindsey.partington@ucdmc.ucdavis.edu
    Atlanta, Georgia
    Emory University – Recruiting
    Principal Investigator: Jeannie Visootsak, MD
    Contact: Krista Charen    404-778-8479    kharkre@emory.edu<
    Chicago, Illinois
    Rush University Medical Center
    Principal Investigator: Elizabeth M Berry-Kravis, MD
    Contact: Jamie A Chin    (312) 942-0025  Jamie_A_Chin@rush.edu
    Worcester, Massachusetts
    University of Massachusetts Medical School
    Principal Investigator: Jean Frazier, MD
    Contact: Ann Foley    774-455-4103    ann.foley@umassmed.edu
    NYC, New York     (click for flyer)
    Mount Sinai School of Medicine
    Principal Investigator: Alexander Kolevzon, MD
    Contact: Hillary Rieger  212-241-2826   hillary.rieger@mssm.edu
    Cincinnati, Ohio
    Cincinnati Children’s Hospital Medical Center
    Principal Investigator: Craig Erickson, MD
    Contact: Bridget Crippen bridget.crippen@cchmc.org or Kaela O’Brien kaela.obrien@cchmc.org
    Lewisburg, Pennsylvania
    Geisinger Autism & Developmental Medicine Institute
    Principal Investigator: Thomas Challman, M.D.
    Contact: Margaret King, Ph.D. (570)-522-9438  mking1@geisinger.edu
    Media, Pennsylvania
    Suburban Research Associates
    Principal Investigator: Shivkumar Hatti, MD
    Contact: Nathan Blubaugh    610-891-9024 ext 103    nblubaugh@suburbanresearch.com
    or Contact: Nikki Thomas    610-891-7200    Nthomas@suburbanresearch.com
    Denver, Colorado
    Children’s Hospital Colorado
    Principal Investigator: Nicole Tartaglia, MD
    Contact: Nanastasia Welnick    720-777-8608   Nanastasia.Welnick@childrenscolorado.org

 

Alcobra’s metadoxine trial has completed recruiting.  Learn more about it at Clinicaltrials.gov at http://clinicaltrials.gov/ct2/show/NCT02126995

  • Details

    The study enrolls eligible young men with FXS, ages 18-24, from around the world, and includes:
    · One visit, lasting several days, to the NIH Clinical Center, in Bethesda, Maryland.
    · Assessment by physicians
    · Blood draw, Two brain scans (PET & MRI), possible sedation
    · Travel, food, and lodging are covered and include the patient and one or two accompanying family members.
    · Compensation is paid for your time and assistance.Please consider enrolling your child in our clinical research study of FXS. If you would like to participate, be on our mailing list, be contacted in case of future studies, or would simply like to have more information: Please call Inna Loutaev, +1 301 496 4707, or E-mail loutaev.inna@nih.gov, or visit our website: http://patientinfo.nimh.nih.gov/Department of Health & Human Services, National Institutes of Health, National Institute of Mental Health, www.clinicaltrials.gov 06-M-0214

~

Completed Clinical Trials funded by FRAXA

~

For all Fragile X medication trials visit http://www.clinicaltrials.gov/ct2/results?term=fragile+x

To learn how trials work, visit http://clinicaltrials.gov/ct2/info/understand